_the-propel-clinical-trial-exploring-olaparib-plus-abiraterone-in-mcrpc-preview-1.jpg "The PROpel clinical trial exploring olaparib plus abiraterone in mCRPC from olaparib prostate cancer Video Screenshot Preview 1")
Gallery_the-propel-clinical-trial-exploring-olaparib-plus-abiraterone-in-mcrpc-preview-3.jpg "The PROpel clinical trial exploring olaparib plus abiraterone in mCRPC from olaparib prostate cancer Video Screenshot Preview 3")
Gallery_the-propel-clinical-trial-exploring-olaparib-plus-abiraterone-in-mcrpc-preview-hqdefault.jpg "The PROpel clinical trial exploring olaparib plus abiraterone in mCRPC from olaparib prostate cancer Video Screenshot Preview hqdefault")
GalleryPlay Video:
(Note: The default playback of the video is HD VERSION. If your browser is buffering the video slowly, please play the REGULAR MP4 VERSION or Open The Video below for better experience. Thank you!)
Jump To Video Parts
⏲ Duration: 1 minute 45 seconds
👁 View: 248 times
Play Audio:👁 View: 248 times
Description:
VJOncology
VJOncology
Share with your friends:
Whatsapp | Viber | Telegram | Line | SMS
Email | Twitter | Reddit | Tumblr | Pinterest
Related Videos
_asco-2023-highlights-and-analysis.webp "Associate Prof Bishal Gyawali discusses several presentations that on topics ranging from adjuvant treatments, neo-adjuvant treatments and supportive care, across a range of cancer types. He concludes by giving his opinion on issues with drug approval. nnThe presentations referred to are:nn1.Overall survival analysis from the ADAURA trial of adjuvant osimertinib in patients with resected EGFR‑mutated (EGFRm) stage IB–IIIA non-small cell lung cancer (NSCLC)n2.Phase III NATALEE trial of riboci")
_parpi-olaparib-for-the-targeted-treatment-of-metastatic-prostate-cancer.webp "Vall d'Hebron Institute of Oncology - VHIO")
_parp-inhibitors-for-metastatic-hormone-sensitive-prostate-cancer.webp "VJOncology")
_asco-2018-novel-treatment-strategies-in-prostate-cancer-therapeutics.webp "Dr Neal Shore speaks to Prof Karim Fizazi about the changing landscape of treatments for prostate cancer, discussing immunotherapies, PARP inhibitors and PSMA testing as future targets and treatments.nnDr Fizazi highlights that anti-PD1 treatment (pembrolizumab) may provide benefit for metastatic castration resistant patients following antiandrogen treatment (5 of the 28 patients in the trial had a PSA decline of50%). nnTrials building on immune checkpoint therapies with novel combinations to")
_propel-olaparib-plus-abiraterone-as-1l-treatment-for-metastatic-crpc.webp "VJOncology")
_profound-parp-inhibitor-olaparib-compared-with-new-hormonal-agents-in-advanced-castration-resistant-prostate-cancer.webp "Prof Maha Hussain speaks to ecancer at ESMO 2019 in Barcelona about data from the PROfound trial comparing the PARP inhibitor olaparib with new hormonal agents in advanced castration resistant prostate cancer.nnShe reports that in cohort A (patients with BRCA1, BRCA2 or ATM genes) progression free survival was over double in favour of the olaparib and in the overall population of cohort A and cohort B (alterations in other genes involved in DNA repair) there were similar trends.nnProf Hussain be")
⏲ 3 min 98 sec ✓ 30-Sep-2019
_rucaparib-and-olaparib-two-new-treatments-approved-for-advanced-prostate-cancer-124-pcri.webp "Prostate Cancer Research Institute")
⏲ 5 minutes 15 seconds 👁 1.8K
_parp-inhibitors-for-prostate-cancer.webp "Cleveland Clinic")
_asco-2023-highlights-and-analysis.jpg)
_parpi-olaparib-for-the-targeted-treatment-of-metastatic-prostate-cancer.jpg)
_parp-inhibitors-for-metastatic-hormone-sensitive-prostate-cancer.jpg)
_asco-2018-novel-treatment-strategies-in-prostate-cancer-therapeutics.jpg)
_propel-olaparib-plus-abiraterone-as-1l-treatment-for-metastatic-crpc.jpg)
_profound-parp-inhibitor-olaparib-compared-with-new-hormonal-agents-in-advanced-castration-resistant-prostate-cancer.jpg)
_rucaparib-and-olaparib-two-new-treatments-approved-for-advanced-prostate-cancer-124-pcri.jpg)
_parp-inhibitors-for-prostate-cancer.jpg)
![[+]](/images/menu.gif){kind=small}